Provided by Tiger Trade Technology Pte. Ltd.

Relay Therapeutics

8.50
+0.910011.99%
Post-market: 8.560.0600+0.71%17:24 EST
Volume:2.43M
Turnover:20.31M
Market Cap:1.47B
PE:-4.86
High:8.64
Open:7.57
Low:7.42
Close:7.59
52wk High:9.04
52wk Low:1.78
Shares:173.32M
Float Shares:102.63M
Volume Ratio:0.79
T/O Rate:2.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7494
EPS(LYR):-2.3638
ROE:-41.14%
ROA:-25.37%
PB:2.42
PE(LYR):-3.60

Loading ...

Relay Therapeutics : Oppenheimer Raises to Outperform From Perform

THOMSON REUTERS
·
Jan 26

Relay Therapeutics Raised to Outperform From Perform by Oppenheimer

Dow Jones
·
Jan 26

Oppenheimer Upgrades Relay Therapeutics to Outperform From Market Perform, Price Target is $14

MT Newswires Live
·
Jan 26

Relay Therapeutics (RLAY): Valuation Check After Encouraging New Zovegalisib Breast Cancer Data

Simply Wall St.
·
Dec 26, 2025

ADVISORY-Alert from Equity-Insider.com was published in error and has been withdrawn

Reuters
·
Dec 17, 2025

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

THOMSON REUTERS
·
Dec 17, 2025

Will Early Zovegalisib Data in HR+/HER2- Breast Cancer Change Relay Therapeutics' (RLAY) Narrative?

Simply Wall St.
·
Dec 14, 2025

Relay Therapeutics Raised to Overweight From Equal-Weight by Wells Fargo

Dow Jones
·
Dec 13, 2025

Sector Update: Health Care Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Dec 12, 2025

Relay Therapeutics Reports 'Robust Activity' in Study of Zovegalisib to Treat Breast Cancer

MT Newswires Live
·
Dec 12, 2025

Relay Therapeutics Reports Promising Zovegalisib Results in Phase 3 Breast Cancer Trial

Reuters
·
Dec 12, 2025

Barclays Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

TIPRANKS
·
Nov 24, 2025

Relay Therapeutics (RLAY): A Fresh Board and Narrower Losses—What Does It Mean for Valuation?

Simply Wall St.
·
Nov 17, 2025

Do New Board Appointments Signal a Strategic Shift for Relay Therapeutics (RLAY) as Cash Outlook Improves?

Simply Wall St.
·
Nov 11, 2025

Stock Track | Relay Therapeutics Plummets 7.81% in Pre-market Following Q3 Earnings Miss and Wider Net Loss

Stock Track
·
Nov 07, 2025

Bank of America Securities Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

TIPRANKS
·
Nov 07, 2025

Stock Track | Relay Therapeutics Plunges Nearly 6% After Q3 Earnings Miss and Higher Net Loss

Stock Track
·
Nov 07, 2025

Relay Therapeutics slightly misses Q3 net loss estimates, expects cash reserves to fund operations into 2029

Reuters
·
Nov 07, 2025

Relay Therapeutics Expands Board with New Appointments

TIPRANKS
·
Nov 07, 2025

Relay Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Lonnel Coats

Reuters
·
Nov 07, 2025